Developing an mRNA-based cancer vaccine, BioNTech has announced its plans for its first center where candidate vaccines will be tested. The first clinical trial center will open in Taiwan.
BioNTech, which has made a name for itself with the COVID-19 vaccine it has developed, and which Uğur Şahin and Özlem Türeci are among the founders, shared an important announcement. The company, which is trying to find a solution to cancer by making use of mRNA (messenger RNA), first regional clinical trial center announced that it will open.
According to the announcement shared by BioNTech, the first center is for the Asia-Pacific region. in Taiwan will be established. At the center, clinical trials of the candidate cancer vaccine BNT113 developed by the company will be conducted.
On which cancer types will the first candidate cancer vaccine be tested?
BioNTech has announced that the clinical trials of the candidate vaccine, named BNT113, will take place at the center for the first time. on head and neck cancer shared to do. However, the company shared that clinical trials may be conducted in various countries in the East Asian region for different candidate vaccines in the future.
BioNTech shared that as of today, it hosts 18 candidate vaccines and 23 ongoing clinical trials in its oncology department.
Source :
https://investors.biontech.de/news-releases/news-release-details/biontech-announces-plans-clinical-trial-hub-taiwan-mrna-based